Richard James Clark

Title: Richard James Clark: Innovator in Alpha-Conotoxin Peptide Research

Introduction: Richard James Clark is a prominent inventor based in Chapel Hill, Australia, known for his contributions to the field of pharmaceutical science. With a total of three patents to his name, Clark’s work primarily focuses on alpha-conotoxin peptides, which have significant implications for medical treatments involving nicotinic acetylcholine receptors and voltage-gated calcium channels.

Latest Patents: Clark’s latest patents demonstrate his innovative approach to peptide research. The first, titled "Alpha Conotoxin Peptides," elucidates methods for preparing alpha-conotoxin peptides and details their pharmaceutical compositions. These compositions are intended for the treatment or prevention of conditions associated with nicotinic acetylcholine receptors. His second patent, "Cyclised Alpha-Conotoxin Peptides," outlines an oral or enteral pharmaceutical preparation that includes synthetically cyclised alpha-conotoxin peptides. These peptides are characterized by an amide cyclised backbone, with no free N- or C-terminus, and are designed to inhibit nicotinic acetylcholine receptors effectively.

Career Highlights: Clark is affiliated with the University of Queensland, where he conducts significant research in the field of pharmacology and peptide chemistry. His academic background and expertise allow him to contribute to innovative solutions for complex medical challenges.

Collaborations: Working alongside talented colleagues such as David James Craik and Norelle Lee Daly, Clark has fostered a collaborative environment that enhances the potential for groundbreaking discoveries in peptide research.

Conclusion: Richard James Clark's inventive work in alpha-conotoxin peptides reflects his commitment to advancing pharmaceutical science. His patents pave the way for potential treatments that target crucial biological receptors, highlighting Clark as a key figure in the field of medical innovation.